logo
  Join        Login             Stock Quote

Spectrum Pharma (SPPI) Expands Manufacturing Capacity To Lift Colorectal Cancer Therapy Supply

 November 27, 2012 09:09 AM
 


(By Balaseshan) Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) said it expanded manufacturing capacity to ensure long-term supply of Fusilev to treat advanced metastatic colorectal cancer. Following the news, shares rose 1.95% in premarket.

The U.S. Food & Drug Administration (FDA) has approved an additional manufacturing facility for the production of Fusilev (levoleucovorin) for injection.

Spectrum has continued to increase the number of qualified third-party manufacturing sites approved for Fusilev production since this product was approved in 2011 for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.

[Related -Spectrum Pharmaceuticals, Inc. (SPPI) Reports Positive Data In Cancer Study]

Fusilev, a novel folate analog, is approved as a ready-to-use solution (Fusilev Injection), and as freeze-dried powder (Fusilev for Injection). Fusilev is indicated for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.

Fusilev is also indicated for rescue after high-dose methotrexate therapy in osteosarcoma. Fusilev is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.

Fusilev, under various trade names, is marketed outside the United States by Pfizer (NYSE: PFE), Sanofi-Aventis (NYSE: SNY), and Takeda.

[Related -Futures Gain After Claims Data; Amazon.Com (AMZN) Drops]

According to the National Cancer Institute, Colorectal Cancer is the third most commonly diagnosed cancer in the U.S. There were about 141,210 new cases of Colorectal Cancer diagnosed in 2011, almost 400 per day. 1.11 million people are currently living with colorectal cancer in the U.S., and 49,380 deaths were estimated in 2011, almost 136 per day.

SPPI closed Monday's regular session at $11.28. The stock has been trading between $9.31 and $17.48 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageHow the Chinese Slowdown Will Impact Your Investments

Most countries would find a quarterly growth rate of 7.3% a cause for a read on...

article imageHow To Profit From Foreign Investment In Real Estate

Though investors don't always capitalize on it, history has a way of repeating itself. In fact, when I saw read on...

article imageAnother Round Of Upbeat US Macro Reports

The US economy grew faster than expected in this year’s third quarter, according to this morning’s read on...

article imageDistinguishing The Fed's Securities Purchases From Monetary Expansion

There has been a bit of confusion about what today's FOMC announcement means with respect to Quantitative read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.